Imara announces opening of higher dose arms in global phase 2b clinical trials of imr-687 for sickle cell disease and beta-thalassemia

Independent data monitoring committees endorse opening higher dose imr-687 treatment arms in ongoing ardent and forte phase 2b clinical trials after review of safety and tolerability data at lower doses

ELVN Ratings Summary

ELVN Quant Ranking